Press Releases

Sign up for Email Alerts Press Release RSS

09/28/2019
Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer
Term:BMS
Language:English
09/28/2019
Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
Term:Corporate/Financial News
Language:English
09/28/2019
Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients
Term:Corporate/Financial News
Language:English
09/24/2019
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have...
Term:Corporate/Financial News
Language:English
09/23/2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Term:Corporate/Financial News
Language:English
09/20/2019
Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights
Term:Bristol-Myers
Language:English
09/19/2019
Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers
Term:Corporate/Financial News
Language:English
09/12/2019
Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019
Term:Corporate/Financial News
Language:English
09/11/2019
Bristol-Myers Squibb Board Announces Election of Three New Directors
Term:Corporate/Financial News
Language:English
09/11/2019
Bristol‑Myers Squibb Announces Dividend
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm